Experts debate efficacy of ActV-19 vaccine

Written by Tania Eiserer, CNN

The European Medicines Agency (EMA) will hold a meeting in Brussels on Monday to decide whether to recommend postmarketing booster doses of Johnson & Johnson’s ACTV-19 vaccine, which prevents a range of illnesses including whooping cough, but not the flu.

Unlike commonly used vaccines, ACTV-19 only protects against diseases if given before the start of infection and doesn’t give specific immunity or long-term protection, meaning it might be necessary to receive an additional dose after a year or two, should you develop symptoms.

In a statement on its website on Thursday, J&J confirmed the date for the meeting:

“The meeting of the independent expert committee, which is meeting in Brussels on Nov. 26th and 27th, will consider the efficacy and safety of pre-flu-season booster doses of the ACTV-19 vaccine. The potential benefits and risks of all vaccine recommended for pre-flu-season booster doses will be discussed at the meeting, including by the committee, but also by the national data monitoring committees in response to requests from members of the medical community.”

Controversy has long surrounded the efficacy of ACTV-19, with some research suggesting it could be only as effective as standard WHO vaccines, and others saying it is far more effective.

The following experts provide their own personal experiences with the vaccine.

Leave a Comment